Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 43

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 43
---
 Three-Month Period EndedSix-Month Period Ended($ in millions)June 27, 2025June 28, 2024June 27, 2025June 28, 2024Sales$1,777 $1,770 $3,457 $3,515 Operating profit (loss)(239)233 (38)468 Depreciation45 41 90 79 Amortization of intangible assets150 140 299 281 Operating profit (loss) as a % of sales(13.4)%13.2 %(1.1)%13.3 %Depreciation as a % of sales2.5 %2.3 %2.6 %2.2 %Amortization as a % of sales8.4 %7.9 %8.6 %8.0 %

Sales Growth (Decline) and Core Sales Decline

% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (decline) (GAAP)0.5 %(1.5)%Impact of:Acquisitions(1.5)%(1.5)%Currency exchange rates (1.5)%(0.5)%Core sales decline (non-GAAP)(2.5)%(3.5)%

Price increases in the segment contributed 0.5% to the change in sales on a year-over-year basis during both the three and six-month periods ended June 27, 2025 and are reflected as a component of core sales above.

Total segment sales increased 0.5% and decreased 1.5% during the three and six-month periods ended June 27, 2025, respectively.  The sales increase during the three-month period was driven by the impact of an acquisition and currency exchange rates, partially offset by a decline in core sales.  The sales decline during the six-month period was primarily a result of decreased core sales, partially offset by the impact of acquisitions and to a lesser extent the impact of currency exchange rates.  The year-over-year decrease in total segment core sales in both the three and six-month periods was driven by declines in both consumables and equipment.  Lower funding levels at emerging biotechnology customers and in the academic and government end-markets reduced demand for